| Citation: |
WEI Xiaoting, BAI Xue, MAO Lili, CHI Zhihong, SHENG Xi'nan, CUI Chuanliang, WANG Xuan, LIAN Bin, TANG Bixia, YAN Xieqiao, LI Siming, ZHOU Li, GUO Jun, SI Lu. Efficacy and Safety of Vemurafenib in Acral and Mucosal Melanoma Patients with BRAF Gene Mutation[J]. Cancer Research on Prevention and Treatment, 2018, 45(11): 879-882. DOI: 10.3971/j.issn.1000-8578.2018.18.0250
|
To explore the efficacy and safety of Vemurafenib in acral and mucosal melanoma patients with BRAF gene mutation.
We retrospectively analyzed the clinical data of 24 patients diagnosed as BRAF gene-mutant acral melanoma (AM) or mucosal melanoma (MM) hospitalized in Peking University Cancer Hospital from January 2011 to January 2016. All patients had died by the follow-up cutoff date of January 2017. Fisher exact test was used to detect the difference of baseline characteristics between AM and PM patients. Kaplan-Meier method was used for the estimation of overall survival (OS) and progression-free survival (PFS). We compared patients' survival data between two melanoma types using Log rank test.
There was no statistical difference in baseline characteristics between AM and MM patients. Overall median OS and PFS were 8.0 and 4.9 months. No statistical difference was found in median OS, median PFS or disease control rate. The severity of most adverse events was less than grade 3. Vemurafenib was well tolerated during patients' treatment.
Vemurafenib has acceptable efficacy and safety in BRAF-gene-mutant AM and MM patients, which is similar to that in cutaneous melanoma patients.
| [1] |
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-86. doi: 10.1002/ijc.29210
|
| [2] |
Kim KB, Kefford R, Pavlick AC, et al. Phase Ⅱ study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor[J]. J Clin Oncol, 2013, 31(4): 482-9. doi: 10.1200/JCO.2012.43.5966
|
| [3] |
Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation[J]. N Engl J Med, 2011, 364(26): 2507-16. doi: 10.1056/NEJMoa1103782
|
| [4] |
Robert C, Long G V, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation[J]. N Engl J Med, 2015, 372(4): 320-30. doi: 10.1056/NEJMoa1412082
|
| [5] |
Si L, Kong Y, Xu X, et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort[J]. Eur J Cancer, 2012, 48(1): 94-100. doi: 10.1016/j.ejca.2011.06.056
|
| [6] |
Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma[J]. N Engl J Med, 2010, 363(9): 809-19. doi: 10.1056/NEJMoa1002011
|
| [7] |
Safaee Ardekani G, Jafarnejad SM, Khosravi S, et al. Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma[J]. Br J Dermatol, 2013, 169(2): 320-8. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=1699f7165f0b3f7a59a7356460ee5a4c
|
| [8] |
Postow MA, Hamid O, Carvajal RD. Mucosal melanoma: pathogenesis, clinical behavior, and management[J]. Curr Oncol Rep, 2012, 14(5): 441-8. doi: 10.1007/s11912-012-0244-x
|
| [9] |
Spencer KR, Mehnert JM. Mucosal Melanoma: Epidemiology, Biology and Treatment[J]. Cancer Treat Res, 2016, 167: 295-320. doi: 10.1007/978-3-319-22539-5
|
| [10] |
Butler M, Hamid O, Ribas A, et al. Efficacy of pembrolizumab in patients with advanced mucosal melanoma enrolled in the KEYNOTE-001, 002, and 006 studies[J]. Eur J Cancer, 2017, 72(1): S123. http://cn.bing.com/academic/profile?id=39274f6e8192eb1d7cae3d272c494ed0&encoded=0&v=paper_preview&mkt=zh-cn
|
| [11] |
Kong Y, Si L, Zhu Y, et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma[J]. Clin Cancer Res, 2011, 17(7): 1684-91. doi: 10.1158/1078-0432.CCR-10-2346
|
| [12] |
Bai X, Mao LL, Chi ZH, et al. BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma[J]. Neoplasma, 2017, 64(4): 626-32. doi: 10.4149/neo_2017_419
|
| [13] |
Chapman PB, Hauschild A, Robert C, et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation[J]. New Engl J Med, 2011, 364(26): 2507-16. doi: 10.1056/NEJMoa1103782
|
| [14] |
Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib[J]. N Engl J Med, 2012, 366(8): 707-14. doi: 10.1056/NEJMoa1112302
|
| [15] |
Larkin J, Del Vecchio M, Ascierto PA, et al. Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study[J]. Lancet Oncol, 2014, 15(4): 436-44. doi: 10.1016/S1470-2045(14)70051-8
|
| [16] |
Balmelli C, Mark M, Spirig C, et al. Long-term tolerability of the BRAF inhibitor vemurafenib in patients with metastatic melanoma: current study data and real-life observations[J]. memo-Mag Eur Med Oncol, 2014, 7(3): 181-6. doi: 10.1007/s12254-014-0156-6
|
| [17] |
Blank CU, Larkin J, Arance AM, et al. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF(V600) mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis[J]. Eur J Cancer, 2017, 79: 176-84. doi: 10.1016/j.ejca.2017.04.007
|
| [18] |
国家食品药品监督管理总局.药品信息-维莫非尼[EB/OL]. [2017-12-25]. http://app2.sfda.gov.cn/datasearchp/index1.do?tableId=36&tableName=TABLE36&tableView=%BD%F8%BF%DA%D2%A9%C6%B7&Id=16506.China
Food and Drug Administration. Medicine information- Vemurafenib film-coated tablets[EB/OL]. [2017-12-25] http://app2.sfda.gov.cn/datasearchp/index1.do?tableId=36&tableName=TABLE36&tableView=%BD%F8%BF%DA%D2%A9%C6%B7&Id=16506.
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: